MKI67 and breast cancer: In conclusion, despite the limitations due to the retrospective nature of the study, our findings support the importance of IHC-based evaluation of PR expression levels combined with Ki67 status to sub-classify, among patients with Luminal-B like BC, groups with different prognosis, which could be useful in modulating and personalizing BC adjuvant treatments.